Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection

Abstract

AbstractBACKGROUNDThe grim (<10% 5-year) survival rates for pancreatic ductal adenocarcinoma (PDAC) are attributed to its complex intrinsic biology and most often late-stage detection. The overlap of symptoms with benign gastrointestinal conditions in early stage further complicates timely detection. The suboptimal diagnostic performance of carbohydrate antigen (CA) 19-9 and elevation in benign hyperbilirubinaemia undermine its reliability, leaving a notable absence of accurate diagnostic biomarkers. Using a selected patient cohort with benign pancreatic and biliary tract conditions we aimed to develop a biomarker signature capable of distinguishing patients with non-specific yet concerning clinical presentations, from those with PDAC.METHODS539 patient serum samples collected under the Accelerated Diagnosis of neuro Endocrine and Pancreatic TumourS (ADEPTS) study (benign disease controls and PDACs) and the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, healthy controls) were screened using the Olink Oncology II panel, supplemented with five in-house markers. 16 specialized base-learner classifiers were stacked to select and enhance biomarker performances and robustness in blinded samples. Each base-learner was constructed through cross-validation and recursive feature elimination in a discovery set comprising approximately two thirds of the ADEPTS and UKCTOCS samples and contrasted specific diagnosis with PDAC.RESULTSThe signature which was developed using diagnosis-specific ensemble learning demonstrated predictive capabilities outperforming CA19-9 and individual biomarkers in both discovery and validation sets. An AUC of 0.98 (95% CI 0.98 – 0.99) and sensitivity of 0.99 (95% CI 0.98 - 1) at 90% specificity was achieved with the ensemble method, which was significantly larger than the AUC of 0.79 (95% CI 0.66 - 0.91) and sensitivity 0.67 (95% CI 0.50 - 0.83), also at 90% specificity, for CA19- 9, in the discovery set (p=0.0016 and p=0.00050, respectively). During ensemble signature validation, an AUC of 0.95 (95% CI 0.91 – 0.99), sensitivity 0.86 (95% CI 0.68 - 1), was attained compared to an AUC of 0.80 (95% CI 0.66 – 0.93), sensitivity 0.65 (95% CI 0.48 – 0.56) at 90% specificity for CA19-9 alone (p=0.0082 and p=0.024, respectively). When validated only on the benign disease controls and PDACs collected from ADEPTS, the diagnostic-specific signature achieved an AUC of 0.96 (95% CI 0.92 – 0.99), sensitivity 0.82 (95% CI 0.64 – 0.95) at 90% specificity, which was still significantly higher than the performance for CA19-9 taken as a single predictor, AUC of 0.79 (95% CI 0.64-0.93) and sensitivity of 0.18 (95% CI 0.03 – 0.69) (p= 0.013 and p=0.0055, respectively).CONCLUSIONOur ensemble modelling technique outperformed CA19-9, individual biomarkers and prevailing algorithms in distinguishing patients with non-specific but concerning symptoms from those with PDAC, with implications for improving its early detection in individuals at risk.